MedTrace Logo

Mesenchymal Stem Cell Infusion as Prevention for Graft Rejection and Graft-versus-host Disease

NCT00504803 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2011-09-02

No results posted yet for this study

Summary

Mesenchymal Stem Cell Infusion as Prevention for Graft Rejection and Graft-Versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation With Nonmyeloablative Conditioning from HLA-mismatched PBSC or cord blood: a Pilot Study

Conditions

Interventions

PROCEDURE

Mesenchymal stem cell infusion

Infusion of mesenchymal stem cells on the same day as hematopoietic stem cell infusion.

Sponsors & Collaborators

  • University of Liege

    lead OTHER

Principal Investigators

  • Frederic Baron, MD, PhD · CHU-ULg

  • Yves Beguin, MD, PhD · CHU-ULg

  • Chantal Lechanteur, PhD · CHU-ULg

  • Etienne Baudoux, MD · CHU-ULg

  • Evelyne Willems, MD · CHU-ULg

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-12-31
Primary Completion
2010-12-31
Completion
2010-12-31

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00504803 on ClinicalTrials.gov